{"Clinical Trial ID": "NCT00320541", "Intervention": ["INTERVENTION 1:", "- Paclitaxel Plus Bevacizumab (PB)", "Paclitaxel 90 milligrams per square metre (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered intravenously on days 1 and 15 every 28 days", "INTERVENTION 2:", "- Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)", "Paclitaxel 90 milligrams per square metre (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered intravenously on days 1 and 15 every 28 days"], "Eligibility": ["Incorporation criteria:", "Women diagnosed with breast cancer and cancer spread to areas far away from the breast or organs.", "Must be able to measure the disease by specific medical parameters", "May have received treatment for breast cancer at the beginning of the disease", "\u2022 May be limited in physically difficult activity but able to perform light work.", "\u2022 Must have an adequate organ function as seen in the blood test results.", "- Excluded", "Criteria:", "The cancer that spread to the brain.", "Unstable heart problems", "- Unstable hypertension.", "\u2022 Treatment of breast cancer after the disease has considered spreading to other regions or organs.", "Unable to agree on study requirements"], "Results": ["Performance measures:", "Overall response rate (OR)", "Response defined by the criteria for assessing response in solid tumours (RCIST): complete response (CR)=disappearance of all target lesions; partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; progressive disease = 20% increase in the sum of the longest diameter of target lesions; stable disease = small changes that do not meet the above criteria.", "Time frame: start and every 2 cycles (approximately 8 weeks) of treatment for measured progressive disease (PD) and post-therapy until initiation of DP or other treatment (up to 35 months)", "Results 1:", "- Arm/group title: Paclitaxel Plus Bevacizumab (PB)", "Paclitaxel 90 milligrams per square metre (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered intravenously on days 1 and 15 every 28 days", "Total number of participants analysed: 94", "Average (95% confidence interval)", "Unit of measure: proportion of respondents 0.489 (0.385 to 0.595)", "Results 2:", "- Arm/group title: Paclitaxel Plus Bevacizumab Plus Gemmitabine (PB+G)", "Paclitaxel 90 milligrams per square metre (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered intravenously on days 1 and 15 every 28 days", "Total number of participants analysed: 92", "Average (95% confidence interval)", "Unit of measure: proportion of responders 0.587 (0.479 to 0.689)"], "Adverse Events": ["Undesirable Events 1:", "Total: 27/94 (28.72%)", "Anemia 2/94 (2.13 per cent)", "- Febrile neutropenia 2/94 (2.13 per cent)", "- Leucopenia 1/94 (1.06%)", "Neutropenia 0/94 (0.00 %)", "Thrombocytopenia 1/94 (1.06%)", "Arrhythmia 0/94 (0.00 %)", "Atrial fibrillation 0/94 (0.00 %)", "- Congestive heart failure 0/94 (0.00 %)", "Cardiomyopathy 0/94 (0.00 %)", "Pericardial infusion 0/94 (0.00 %)", "Tachycardia 0/94 (0.00 %)", "Adverse Events 2:", "Total: 36/93 (38.71 per cent)", "Anemia 2/93 (2.15 per cent)", "9/93 (9.68 per cent)", "Leucopenia 3/93 (3.23%)", "Neutropenia 4/93 (4.30%)", "Thrombocytopenia 1/93 (1.08%)", "Arrhythmia 1/93 (1.08%)", "Atrial fibrillation 1/93 (1.08%)", "- Congestive heart failure 3/93 (3.23%)", "Cardiomyopathy 2/93 (2.15 %)", "Pericardial infusion 1/93 (1.08%)", "- Tachycardia 1/93 (1.08%)"]}